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Facial hair growth  
in a patient with psoriasis
Rita S Matos, Tiago Torres
CLINICAL
generalised or localised. Each of these 
types is further divided into congenital 
and acquired subtypes.1 It can be a 
manifestation of a more general medical 
problem. The possible causes of 
acquired hypertrichosis are summarised 
in Table 1.1
Hypertrichosis must not be confused 
with hirsutism, which is defined as 
androgen-induced growth of terminal 
hair in women and children, in a 
male pattern distribution. Hirsutism 
is androgen-dependent, whereas 
hypertrichosis is not.1
Answer 2
The most likely aetiology for 
hypertrichosis in this patient is 
cyclosporine therapy. Cyclosporine is an 
effective drug used for the treatment of 
psoriasis.4–6 It is an immunomodulating 
agent that binds to cyclophilin, a 
cytoplasmic protein. Cyclosporine 
interrupts the signalling pathway for 
interleukin-2 production and inhibits the 
proliferation of cluster of differentiation 
4 (CD4) T-lymphocytes.7 One possible 
mechanism for hypertrichosis may be 
the expression of several growth factors 
and production of other cytokines.2,4 
Hypertrichosis is one of the most 
common side effects of systemic 
cyclosporine therapy, although there 
is considerable variability in the 
reported incidence.8 It is a dose-
dependent phenomenon and usually 
noted a few months after cyclosporine 
therapy begins.1 Other possible 
indications for cyclosporine include 
rheumatic diseases (eg rheumatoid 
arthritis), ulcerative colitis and various 
other immune-mediated diseases. 
Cyclosporine is also the backbone 
of immunosuppression in transplant 
recipients, particularly those with renal 
transplants.3
Case
A woman, 47 years of age, with 
chronic plaque-type psoriasis for the 
past 18 years but otherwise healthy, 
presented complaining of facial hair 
growth three months after starting 
systemic cyclosporine therapy (3.5 
mg/kg/day). The patient had been 
previously treated with topical agents 
and narrowband ultraviolet B (NB-UVB) 
phototherapy. On physical examination, 
she had marked facial hair growth 
and improvement of psoriasis severity 
(Figure 1). No other skin lesions or 
symptoms were detected.
Question 1
What is the pathogenesis of this 
phenomenon?
Question 2
What is the most likely aetiology for 
hypertrichosis in this patient?
Question 3
Are there other possible side effects?
Question 4
How would you manage this patient?
Answer 1
Hypertrichosis is excessive hair growth 
on any part or whole of the body, 
compared with people of the same age, 
sex and racial group.1 The underlying 
pathogenesis remains unknown.2,3 
Hypertrichosis is usually classified as 
Figure 1. Clinical appearance of patient’s facial hair
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or biological agents (anti-TNFα, anti-p40 e 
anti-IL17).10 
When it is not possible to stop 
cyclosporine, hypertrichosis can 
be managed by physical methods 
(eg plucking, waxing, shaving), 
chemical depilation, laser sources or 
pharmacological treatment with topical 
eflornithine.1
Key points
• Hypertrichosis is one of the most 
common side effects of systemic 
cyclosporine therapy. It is dose-
dependent and usually noted a few 
months after beginning therapy.
• Cessation of cyclosporine results in a 
progressive resolution of the induced 
hypertrichosis.
Answer 3
There are other cutaneous side effects 
of cyclosporine, such as epidermal cysts, 
keratosis pilaris, acne, folliculitis and 
sebaceous hyperplasia.8 The other side 
effects are summarised in Table 2.
Answer 4
Cessation of cyclosporine therapy 
results in a progressive resolution of the 
induced hypertrichosis.3,9 The decision to 
discontinue systemic treatment should 
include a risk–benefit assessment for that 
particular patient. The patient’s psoriasis 
will probably be aggravated following 
cyclosporine cessation. Other possible 
systemic treatments can be considered 
on a case-by-case basis. These systemic 
treatments include methotrexate, acitretin 
Table 1. Possible causes for acquired hypertrichosis
Congenital generalised Congenital hypertrichosis lanuginose
Universal congenital hypertrichosis
Acquired generalised Hypertrichosis lanuginosa associated with malignancy
Endocrine disorders (eg thyroid disorders and disorders of 
diencephalon or pituitary)
Malnutrition (eg celiac disease, anorexia nervosa)
Drugs (eg phenytoin, acetazolamide, cyclosporine, penicillamine)
Congenital localised Melanocytic naevi
Lumbosacral hypertrichosis
Acquired localised Becker’s naevus
Porphyria cutanea tarda
Trauma
Infection 
Inflammation (areas overlying thrombophlebitis or chronic 
osteomyelitis or vaccination sites)
Table 2. Side effects of systemic cyclosporine therapy
Cutaneous Hypertrichosis, epidermal cysts, keratosis pilaris, acne, folliculitis, 
sebaceous hyperplasia
Cardiovascular Hypertension, hyperlipidemia (particularly hypertriglyceridemia)
Renal Nephrotoxicity
Neurologic Paresthesia, hyperesthesia, headaches, seizures, psychosis, tremor
Gastrointestinal Nausea, vomiting, diarrhea, anorexia, abdominal discomfort, 
hyperbilirrubinemia
Other Gingival hyperplasia, hyperuricemia, hypomagnesemia
